Ferry Ossendorp

List of Publications by Year
in descending order

161	12,074	22153	29157
papers	citations	59 h-index	104 g-index

164	164	164	14417
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Therapeutic cancer vaccines. Journal of Clinical Investigation, 2015, 125, 3401-3412.	8.2	640
2	Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nature Reviews Cancer, 2016, 16, 219-233.	28.4	580
3	Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors. Journal of Experimental Medicine, 1998, 187, 693-702.	8.5	535
4	CD4 T Cells and Their Role in Antitumor Immune Responses. Journal of Experimental Medicine, 1999, 189, 753-756.	8.5	460
5	Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Current Opinion in Immunology, 2004, 16, 76-81.	5.5	372
6	MHC II in Dendritic Cells is Targeted to Lysosomes or T Cellâ€Induced Exosomes Via Distinct Multivesicular Body Pathways. Traffic, 2009, 10, 1528-1542.	2.7	347
7	CTLs are targeted to kill Î² cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. Journal of Clinical Investigation, 2008, 118, 3390-402.	8.2	315
8	Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. Journal of Cell Biology, 2001, 155, 53-64.	5.2	256
9	Autoreactive CD8 T cells associated with Â cell destruction in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18425-18430.	7.1	252
10	Efficient Identification of Novel Hla-A*0201â€“Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis. Journal of Experimental Medicine, 2001, 193, 73-88.	8.5	236
11	CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials, 2015, 40, 88-97.	11.4	235
12	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine, 2020, 12, .	12.4	229
13	Antigen-Antibody Immune Complexes Empower Dendritic Cells to Efficiently Prime Specific CD8+ CTL Responses In Vivo. Journal of Immunology, 2002, 168, 2240-2246.	0.8	223
14	Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight, 2018, 3, .	5.0	216
15	Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyteâ€Induced Apoptosis. Journal of Experimental Medicine, 2001, 194, 657-668.	8.5	187
16	Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study. Journal of Controlled Release, 2014, 192, 209-218.	9.9	187
17	A Single Residue Exchange Within a Viral CTL Epitope Alters Proteasome-Mediated Degradation Resulting in Lack of Antigen Presentation. Immunity, 1996, 5, 115-124.	14.3	180
18	Immature Dendritic Cells Acquire Cd8+Cytotoxic T Lymphocyte Priming Capacity upon Activation by T Helper Cellâ€Independent orâ€Dependent Stimuli. Journal of Experimental Medicine, 2000, 192, 145-150.	8.5	173

#	Article	IF	Citations
19	Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cellâ€“Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects. Clinical Cancer Research, 2013, 19, 5381-5389.	7.0	172
20	Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells. Journal of Biological Chemistry, 2007, 282, 21145-21159.	3.4	157
21	Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and Tâ€cell activation. European Journal of Immunology, 2013, 43, 2554-2565.	2.9	157
22	Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nature Medicine, 2006, 12, 417-424.	30.7	142
23	The Translocon Protein Sec61 Mediates Antigen Transport from Endosomes in the Cytosol for Cross-Presentation to CD8+ T Cells. Immunity, 2015, 42, 850-863.	14.3	136
24	Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6730-6735.	7.1	132
25	The minor histocompatibility antigen HA-3 arises from differential proteasomeâ€“mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood, 2003, 102, 621-629.	1.4	118
26	Adenosineâ€“deaminaseâ€“deficient mice die perinatally and exhibit liverâ€“cell degeneration, atelectasis and small intestinal cell death. Nature Genetics, 1995, 10, 279-287.	21.4	116
27	PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. OncoImmunology, 2017, 6, e1294299.	4.6	114
28	Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials, 2016, 83, 308-320.	11.4	107
29	Immune Complex-Loaded Dendritic Cells Are Superior to Soluble Immune Complexes as Antitumor Vaccine. Journal of Immunology, 2006, 176, 4573-4580.	0.8	104
30	The Inhibiting Fc Receptor for IgG, FcÎ³RIIB, Is a Modifier of Autoimmune Susceptibility. Journal of Immunology, 2011, 187, 1304-1313.	0.8	103
31	Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28. Journal of Experimental Medicine, 2000, 192, 483-494.	8.5	100
32	Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells. Cancer Immunology Research, 2017, 5, 832-838.	3.4	95
33	Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunological Reviews, 2002, 188, 177-182.	6.0	94
34	Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nature Immunology, 2011, 12, 45-53.	14.5	94
35	Design and evaluation of antigen-specific vaccination strategies against cancer. Current Opinion in Immunology, 2000, 12, 576-582.	5.5	91
36	Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors. Clinical Cancer Research, 2016, 22, 1459-1468.	7.0	90

#	Article	IF	Citations
37	Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. Biomaterials, 2015, 61, 33-40.	11.4	89
38	Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site. Journal of Immunology, 2000, 164, 1898-1905.	0.8	88
39	Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation. Journal of Controlled Release, 2015, 203, 16-22.	9.9	87
40	Ins and Outs of Dendritic Cells. International Archives of Allergy and Immunology, 2006, 140, 53-72.	2.1	83
41	Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict Therapeutic Efficacy against Tumors. Journal of Immunology, 2012, 189, 3397-3403.	0.8	83
42	Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligandâ€“Peptide Conjugates. Cancer Immunology Research, 2014, 2, 756-764.	3.4	83
43	Differential Kinetics of Antigen-Specific CD4+ and CD8+ T Cell Responses in the Regression of Retrovirus-Induced Sarcomas. Journal of Immunology, 2002, 169, 3191-3199.	0.8	82
44	Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles. Journal of Controlled Release, 2016, 226, 98-106.	9.9	82
45	Combined Inhibition of TGF-Î² Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. Cells, 2019, 8, 320.	4.1	82
46	Vaccine-Induced Tumor Necrosis Factorâ€“Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death. Clinical Cancer Research, 2015, 21, 781-794.	7.0	81
47	T cell depletion in transgenic mice carrying a mutant gene for TCR-Î². Nature, 1989, 341, 742-746.	27.8	77
48	Reductionâ€Sensitive Dextran Nanogels Aimed for Intracellular Delivery of Antigens. Advanced Functional Materials, 2015, 25, 2993-3003.	14.9	77
49	Cationic Liposomes Loaded with a Synthetic Long Peptide and Poly(I:C): a Defined Adjuvanted Vaccine for Induction of Antigen-Specific T Cell Cytotoxicity. AAPS Journal, 2015, 17, 216-226.	4.4	77
50	Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. Pharmaceutics, 2020, 12, 1054.	4.5	77
51	Hollow microneedle-mediated micro-injections of a liposomal HPV E743â€“63 synthetic long peptide vaccine for efficient induction of cytotoxic and T-helper responses. Journal of Controlled Release, 2018, 269, 347-354.	9.9	75
52	Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical Recommendations. Journal of Clinical Medicine, 2020, 9, 333.	2.4	72
53	Identification of a Novel HLA-B60-Restricted T Cell Epitope of the Minor Histocompatibility Antigen HA-1 Locus. Journal of Immunology, 2002, 169, 3131-3136.	0.8	71
54	Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells1. Transplantation, 2003, 76, 1608-1615.	1.0	71

#	Article	IF	Citations
55	TLR Ligandâ€“Peptide Conjugate Vaccines. Advances in Immunology, 2012, 114, 177-201.	2.2	71
56	Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. Journal of Autoimmunity, 2011, 37, 151-159.	6.5	66
57	Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: InÂvivo tracking and evaluation of antigen-specific CD8 + T cell immune response. Biomaterials, 2015, 37, 469-477.	11.4	64
58	The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 881-894.	2.3	61
59	Differential Expression Regulation of the Î± and Î² Subunits of the PA28 Proteasome Activator in Mature Dendritic Cells. Journal of Immunology, 2005, 174, 7815-7822.	0.8	60
60	Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines. Cancer Immunology Research, 2017, 5, 222-233.	3.4	60
61	TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. Journal of Clinical Investigation, 2016, 126, 784-794.	8.2	60
62	Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Molecular Immunology, 2009, 46, 1084-1091.	2.2	58
63	Cloning and expression of murine CD27: comparison with 4-1BB, another lymphocyte-specific member of the nerve growth factor receptor family. European Journal of Immunology, 1993, 23, 943-950.	2.9	57
64	Functional characterization of a novel anti-B7 monoclonal antibody. European Journal of Immunology, 1992, 22, 3071-3075.	2.9	56
65	FcÎ³ Receptor IIb Strongly Regulates FcÎ³ Receptor-Facilitated T Cell Activation by Dendritic Cells. Journal of Immunology, 2012, 189, 92-101.	0.8	56
66	Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. European Journal of Immunology, 2002, 32, 2748-2758.	2.9	55
67	Approaches to Improve Chemically Defined Synthetic Peptide Vaccines. Frontiers in Immunology, 2018, 9, 884.	4.8	54
68	Get into the groove! Targeting antigens to MHC class II. Immunological Reviews, 1999, 172, 87-96.	6.0	51
69	Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+T cells upon immune-complex uptake in vivo. Immunology, 2006, 119, 499-506.	4.4	51
70	Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication. , 2018, 6, 146.		50
71	The viral context instructs the redundancy of costimulatory pathways in driving CD8+ T cell expansion. ELife, 2015, 4, .	6.0	48
72	PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors. , 2019, 7, 217.		47

#	Article	IF	Citations
73	Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies. Journal of Controlled Release, 2020, 323, 1-11.	9.9	47
74	Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination. Molecular Pharmaceutics, 2017, 14, 1482-1493.	4.6	46
75	Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Research, 2002, 62, 6187-93.	0.9	46
76	Cytofast: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations. Computational and Structural Biotechnology Journal, 2018, 16, 435-442.	4.1	45
77	Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles. Theranostics, 2019, 9, 6485-6500.	10.0	45
78	A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control. OncoImmunology, 2019, 8, 1652539.	4.6	45
79	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Seminars in Immunology, 2013, 25, 182-190.	5.6	44
80	Cationic Liposomes: A Flexible Vaccine Delivery System for Physicochemically Diverse Antigenic Peptides. Pharmaceutical Research, 2018, 35, 207.	3.5	44
81	Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin. Journal of Immunology, 2000, 165, 869-877.	0.8	43
82	TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. Oncotarget, 2016, 7, 67087-67100.	1.8	43
83	Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors. PLoS ONE, 2011, 6, e16819.	2.5	42
84	Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer. OncoImmunology, 2020, 9, 1673125.	4.6	40
85	Circulating specific antibodies enhance systemic crossâ€priming by delivery of complexed antigen to dendritic cells in vivo. European Journal of Immunology, 2012, 42, 598-606.	2.9	39
86	CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy. Cancer Immunology Research, 2017, 5, 642-653.	3.4	37
87	Receptorâ€Mediated Targeting of Cathepsins in Professional Antigen Presenting Cells. Angewandte Chemie - International Edition, 2009, 48, 1629-1632.	13.8	35
88	New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation. Journal of Immunology, 2013, 191, 4020-4028.	0.8	35
89	Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds. Nanoscale, 2016, 8, 19592-19604.	5.6	35
90	Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo. Molecular Immunology, 2006, 43, 2045-2050.	2.2	32

#	Article	IF	Citations
91	A Dual-Color Bioluminescence Reporter Mouse for Simultaneous in vivo Imaging of T Cell Localization and Function. Frontiers in Immunology, 2018, 9, 3097.	4.8	32
92	N-Tetradecylcarbamyl Lipopeptides as Novel Agonists for Toll-like Receptor 2. Journal of Medicinal Chemistry, 2014, 57, 6873-6878.	6.4	31
93	Cationic synthetic long peptides-loaded nanogels: An efficient therapeutic vaccine formulation for induction of T-cell responses. Journal of Controlled Release, 2019, 315, 114-125.	9.9	31
94	Mechanism of action of PDâ€1 receptor/ligand targeted cancer immunotherapy. European Journal of Immunology, 2021, 51, 1911-1920.	2.9	31
95	Ovalbumin-coated pH-sensitive microneedle arrays effectively induce ovalbumin-specific antibody and T-cell responses in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 310-315.	4.3	30
96	A Novel Role of Complement Factor C1q in Augmenting the Presentation of Antigen Captured in Immune Complexes to CD8+T Lymphocytes. Journal of Immunology, 2007, 178, 7581-7586.	0.8	29
97	Chemical Control over T-Cell Activation in Vivo Using Deprotection of trans-Cyclooctene-Modified Epitopes. ACS Chemical Biology, 2018, 13, 1569-1576.	3.4	29
98	A third vaccination with a single TÂcell epitope confers protection in a murine model of SARS-CoV-2 infection. Nature Communications, 2022, 13, .	12.8	29
99	Steric Hindrance and Fast Dissociation Explain the Lack of Immunogenicity of the Minor Histocompatibility HA-1Arg Null Allele. Journal of Immunology, 2009, 182, 4809-4816.	0.8	28
100	FcRÎ³-Chain ITAM Signaling Is Critically Required for Cross-Presentation of Soluble Antibodyâ€“Antigen Complexes by Dendritic Cells. Journal of Immunology, 2014, 193, 5506-5514.	0.8	28
101	Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences. Journal of Controlled Release, 2018, 285, 56-66.	9.9	28
102	Self-Adjuvanting Cancer Vaccines from Conjugation-Ready Lipid A Analogues and Synthetic Long Peptides. Journal of Medicinal Chemistry, 2020, 63, 11691-11706.	6.4	28
103	Enhanced Cross-Presentation and Improved CD8+ T Cell Responses after Mannosylation of Synthetic Long Peptides in Mice. PLoS ONE, 2014, 9, e103755.	2.5	27
104	The identification of a common pathogen-specific HLA classâ€„Iâ€„A*0201-restricted cytotoxic T cell epitope encoded within the heat shock protein 65. European Journal of Immunology, 2001, 31, 3602-3611.	2.9	26
105	Cd8 Tâ€cell recognition of human 5T4 oncofetal antigen. International Journal of Cancer, 2006, 119, 1638-1647.	5.1	26
106	Photodynamic cancer therapy enhances accumulation of nanoparticles in tumor-associated myeloid cells. Journal of Controlled Release, 2020, 320, 19-31.	9.9	26
107	Local immunomodulation for cancer therapy: Providing treatment where needed. OncoImmunology, 2013, 2, e26493.	4.6	24
108	Dual Synthetic Peptide Conjugate Vaccine Simultaneously Triggers TLR2 and NOD2 and Activates Human Dendritic Cells. Bioconjugate Chemistry, 2019, 30, 1150-1161.	3.6	24

#	Article	IF	Citations
109	Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: Towards synthetic epitope-based vaccines. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3258-3261.	2.2	23
110	2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2249-2251.	2.2	22
111	The Efficiency of Human Cytomegalovirus pp65495â€“503CD8+T Cell Epitope Generation Is Determined by the Balanced Activities of Cytosolic and Endoplasmic Reticulum-Resident Peptidases. Journal of Immunology, 2012, 189, 529-538.	0.8	22
112	Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles. Cancer Immunology, Immunotherapy, 2013, 62, 1161-1173.	4.2	22
113	Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. Vaccine, 2014, 32, 1654-1660.	3.8	22
114	C1q-Dependent Dendritic Cell Cross-Presentation of In Vivoâ€“Formed Antigenâ€“Antibody Complexes. Journal of Immunology, 2017, 198, 4235-4243.	0.8	21
115	Cationic Nanoparticle-Based Cancer Vaccines. Pharmaceutics, 2021, 13, 596.	4.5	21
116	Autophagy regulates longâ€term crossâ€presentation by murine dendritic cells. European Journal of Immunology, 2021, 51, 835-847.	2.9	20
117	Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization. Immunology Letters, 1995, 47, 1-8.	2.5	19
118	Lipophilic Muramyl Dipeptideâ€“Antigen Conjugates as Immunostimulating Agents. ChemMedChem, 2016, 11, 190-198.	3.2	19
119	Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer. Current Pharmaceutical Design, 2015, 21, 4201-4216.	1.9	19
120	New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides. Nuclear Medicine and Biology, 2004, 31, 815-820.	0.6	17
121	Peptides conjugated to 2-alkoxy-8-oxo-adenine as potential synthetic vaccines triggering TLR7. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1340-1344.	2.2	17
122	Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule. OncoImmunology, 2014, 3, e947892.	4.6	16
123	Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System. Journal of Immunology, 2018, 201, 87-97.	0.8	16
124	Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights. International Journal of Molecular Sciences, 2021, 22, 9401.	4.1	16
125	Gamma Irradiation or CD4+-T-Cell Depletion Causes Reactivation of Latent Salmonella enterica Serovar Typhimurium Infection in C3H/HeN Mice. Infection and Immunity, 2005, 73, 2857-2862.	2.2	15
126	Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses. Molecular Immunology, 2018, 93, 115-124.	2.2	15

#	Article	IF	Citations
127	IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation. Journal of Immunology, 2014, 192, 5813-5820.	0.8	14
128	A Restricted Role for FcÎ³R in the Regulation of Adaptive Immunity. Journal of Immunology, 2018, 200, 2615-2626.	0.8	14
129	Doxorubicin Loaded Poloxamer Thermosensitive Hydrogels: Chemical, Pharmacological and Biological Evaluation. Molecules, 2020, 25, 2219.	3.8	14
130	Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology: an International Journal of Immunological Engineering, 1996, 2, 241-251.	2.4	13
131	Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models. Pharmaceutics, 2021, 13, 1470.	4.5	13
132	M1-derived extracellular vesicles enhance photodynamic therapy and promote immunological memory in preclinical models of colon cancer. Journal of Nanobiotechnology, 2022, 20, .	9.1	13
133	Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire. Molecular Immunology, 2014, 62, 129-136.	2.2	12
134	Synthesis and evaluation of fluorescent Pam3Cys peptide conjugates. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3641-3645.	2.2	12
135	FcÎ³R interaction is not required for effective antiâ€PDâ€L1 immunotherapy but can add additional benefit depending on the tumor model. International Journal of Cancer, 2019, 144, 345-354.	5.1	12
136	Zinc-Phthalocyanine-Loaded Extracellular Vesicles Increase Efficacy and Selectivity of Photodynamic Therapy in Co-Culture and Preclinical Models of Colon Cancer. Pharmaceutics, 2021, 13, 1547.	4.5	12
137	Effective CD8+ T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells. Vaccine, 2009, 27, 5252-5258.	3.8	11
138	PD-L1 immune suppression in cancer: Tumor cells or host cells?. OncoImmunology, 2017, 6, e1325982.	4.6	11
139	High FcÎ³R Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy. Journal of Immunology, 2018, 201, 3741-3749.	0.8	11
140	FcÎ³RI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines. Oncotarget, 2018, 9, 29392-29402.	1.8	10
141	Pyroptosis-inducing active caspase-1 as a genetic adjuvant in anti-cancer DNA vaccination. Vaccine, 2022, 40, 2087-2098.	3.8	10
142	DCâ€induced CD8⁺ Tâ€cell response is inhibited by MHC class IIâ€dependent DX5⁺CD4⁺ Treg. European Journal of Immunology, 2009, 39, 1765-1773.	2.9	9
143	Intraendosomal flow cytometry: A novel approach to analyze the protein composition of antigenâ€loaded endosomes. European Journal of Immunology, 2012, 42, 2187-2190.	2.9	9
144	The Optimization of Bioorthogonal Epitope Ligation within MHC-I Complexes. ACS Chemical Biology, 2016, 11, 3172-3178.	3.4	9

#	Article	IF	Citations
145	A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant.. Journal of Clinical Oncology, 2016, 34, TPS3113-TPS3113.	1.6	9
146	Sustained crossâ€presentation capacity of murine splenic dendritic cell subsets in vivo. European Journal of Immunology, 2018, 48, 1164-1173.	2.9	8
147	Distinct antigen uptake receptors route to the same storage compartments for crossâ€presentation in dendritic cells. Immunology, 2021, 164, 494-506.	4.4	8
148	Immunogenicity of rat-neu+ mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment. Scientific Reports, 2020, 10, 3933.	3.3	6
149	Multivalent, Stabilized Mannoseâ€6â€Phosphates for the Targeted Delivery of Tollâ€Like Receptor Ligands and Peptide Antigens. ChemBioChem, 2021, 22, 434-440.	2.6	6
150	Simplified Monopalmitoyl Tollâ€like Receptor 2 Ligand Miniâ€UPam for Selfâ€Adjuvanting Neoantigenâ€Based Synthetic Cancer Vaccines. ChemBioChem, 2021, 22, 1215-1222.	2.6	5
151	Evaluation of the high-pressure extrusion technique as a method for sizing plasmid DNA-containing cationic liposomes. Journal of Liposome Research, 2011, 21, 286-295.	3.3	4
152	Visualization and Quantification of High-Dimensional Cytometry Data using Cytofast and the Upstream Clustering Methods FlowSOM and Cytosplore. Journal of Visualized Experiments, 2019, , .	0.3	4
153	Dominant Antiviral CD8+ T Cell Responses Empower Prophylactic Antibody-Eliciting Vaccines Against Cytomegalovirus. Frontiers in Immunology, 2022, 13, 680559.	4.8	4
154	Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.. Journal of Clinical Oncology, 2021, 39, 2614-2614.	1.6	3
155	Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control. Npj Vaccines, 2022, 7, .	6.0	3
156	A novel virus-like drug conjugate (VDC) in combination with immune checkpoint inhibitors for the treatment of primary tumors and distant metastasis.. Journal of Clinical Oncology, 2022, 40, e14544-e14544.	1.6	2
157	Cationic Nanogels: Reduction-Sensitive Dextran Nanogels Aimed for Intracellular Delivery of Antigens (Adv. Funct. Mater. 20/2015). Advanced Functional Materials, 2015, 25, 2992-2992.	14.9	1
158	Quantification of Lipid and Peptide Content in Antigenic Peptide-loaded Liposome Formulations by Reversed-phase UPLC using UV Absorbance and Evaporative Light Scattering Detection. Journal of Pharmaceutical Sciences, 2022, 111, 1040-1049.	3.3	1
159	Measuring the Antitumor T-Cell Response in the Context of Photodynamic Therapy. Methods in Molecular Biology, 2022, 2451, 579-588.	0.9	1
160	Combination of Photodynamic Therapy and Therapeutic Vaccination. Methods in Molecular Biology, 2022, 2451, 597-604.	0.9	0
161	Combination of Photodynamic Therapy and Immune Checkpoint Blockade. Methods in Molecular Biology, 2022, 2451, 589-596.	0.9	0